Oregon is currently home to 1213 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331
Recruiting
A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis. Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
02/24/2025
Locations: Providence St. Vincent Medical Center, Portland, Oregon
Conditions: In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Register for Updates
Dermal Allograft Augmentation of Large and Massive Rotator Cuff Tears
NCT05981833
Recruiting
The purpose of this study is to compare postoperative healing of large and massive rotator cuff tears with preoperative MRI confirmed fatty infiltration stage II and higher repaired with or without dermal allograft augmentation (DAA).
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
02/21/2025
Locations: Southern Oregon Orthopedics Research Foundation, Medford, Oregon
Conditions: Full-thickness Rotator Cuff Tear
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: LEO Pharma Investigational Site, Portland, Oregon
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971
Recruiting
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Willamette Valley Cancer Institute (Oregon), Eugene, Oregon
Conditions: Small Cell Lung Cancer Extensive Stage
Register for Updates
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
NCT05653882
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Providence Cancer Institute Franz Clinic, Portland, Oregon
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Register for Updates
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
NCT05081024
Recruiting
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with v... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Register for Updates
Conversations With Caregivers About Health and Appearance
NCT06843200
Recruiting
This clinical trial is evaluating the effects of a 2-hour, small group discussion with parents and caregivers of adolescents in Oregon. We will evaluate whether parents'/caregivers' experience reductions in their disordered eating symptoms, mood symptoms, and parent-child relationship quality, relative to parent/caregiver participants in the wait list control. We will also evaluate whether the children of these parents/caregivers experience improvements in their disordered eating and mood sympto... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/18/2025
Locations: University of Oregon, Eugene, Oregon
Conditions: Disordered Eating Behaviors, Depression, Feeding Behaviors, Parent-Child Relations
Register for Updates
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
NCT05878860
Recruiting
This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).
Gender:
MALE
Ages:
6 years and above
Trial Updated:
02/18/2025
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: X-linked Retinoschisis
Register for Updates
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Radiation Retinopathy, Visual Impairment
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
NCT05977907
Recruiting
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Providence Cancer Institute, Portland, Oregon
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates